These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Plant-Fox AS; O'Halloran K; Goldman S Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558 [TBL] [Abstract][Full Text] [Related]
5. Pediatric Gliomas: Molecular Landscape and Emerging Targets. Peeters SM; Muftuoglu Y; Na B; Daniels DJ; Wang AC Neurosurg Clin N Am; 2021 Apr; 32(2):181-190. PubMed ID: 33781501 [TBL] [Abstract][Full Text] [Related]
6. Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Garcia MA; Solomon DA; Haas-Kogan DA Future Oncol; 2016 Jun; 12(12):1493-506. PubMed ID: 27072750 [TBL] [Abstract][Full Text] [Related]
8. Pediatric low-grade glioma in the era of molecular diagnostics. Ryall S; Tabori U; Hawkins C Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789 [TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743 [TBL] [Abstract][Full Text] [Related]
10. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993 [TBL] [Abstract][Full Text] [Related]
11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
12. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Dasgupta T; Haas-Kogan DA Front Oncol; 2013; 3():110. PubMed ID: 23717811 [TBL] [Abstract][Full Text] [Related]
13. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Rizzo D; Ruggiero A; Martini M; Rizzo V; Maurizi P; Riccardi R Biomed Res Int; 2015; 2015():215135. PubMed ID: 26448930 [TBL] [Abstract][Full Text] [Related]
14. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Manoharan N; Liu KX; Mueller S; Haas-Kogan DA; Bandopadhayay P Neoplasia; 2023 Feb; 36():100857. PubMed ID: 36566593 [TBL] [Abstract][Full Text] [Related]
17. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Hargrave D Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006 [TBL] [Abstract][Full Text] [Related]
18. Investigational new drugs for brain cancer. Staedtke V; Bai RY; Laterra J Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161 [TBL] [Abstract][Full Text] [Related]